Oritavancin Free Base | CAS# 171099-57-3 (free base) | Antibacterial

MedKoo Cat#: 414626 | Name: Oritavancin Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oritavancin Free Base is an Antibacterial.

Chemical Structure

Oritavancin Free Base

CAS#171099-57-3 (free base)

Theoretical Analysis

MedKoo Cat#: 414626

Name: Oritavancin Free Base

CAS#: 171099-57-3 (free base)

Chemical Formula: C86H97Cl3N10O26

Exact Mass: 1790.5641

Molecular Weight: 1793.12

Elemental Analysis: C, 57.61; H, 5.45; Cl, 5.93; N, 7.81; O, 23.20

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

171099-57-3 (free base); 192564-14-0 (diphosphate)

Synonym

Oritavancin Free Base; LY333328; LY 333328; LY-333328

IUPAC/Chemical Name

(4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin

InChi Key

VHFGEBVPHAGQPI-LXKZPTCJSA-N

InChi Code

InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1

SMILES Code

CN[C@@H](C(N[C@@H]1[C@@H](c2cc(Cl)c(Oc3c(O[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O[C@H]5C[C@](NCc6ccc(c7ccc(Cl)cc7)cc6)([C@H]([C@@H](O5)C)O)C)O)O)CO)c(Oc8c(Cl)cc([C@H]([C@@H]9NC([C@@H](c%10cc(c%11c([C@@H](C(O)=O)NC9=O)cc(O)cc%11O)c(O)cc%10)NC([C@@H]%12NC([C@@H](NC1=O)CC(N)=O)=O)=O)=O)O[C@H]%13C[C@](N)([C@H]([C@@H](O%13)C)O)C)cc8)cc%12c3)cc2)O)=O)CC(C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,793.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Oritavancin. 2021 Jun 21. PMID: 29999750. 2: Scoble PJ, Reilly J, Tillotson GS. Real-World Use of Oritavancin for the Treatment of Osteomyelitis. Drugs Real World Outcomes. 2020 Jun;7(Suppl 1):46-54. doi: 10.1007/s40801-020-00194-8. PMID: 32588387; PMCID: PMC7334326. 3: Flüh G, Seifert H, Kaasch AJ. Oritavancin: an update. Future Microbiol. 2018 Jun 1;13:727-729. doi: 10.2217/fmb-2017-0310. Epub 2018 May 25. PMID: 29799267. 4: Mattox J, Belliveau P, Durand C. Oritavancin: A Novel Lipoglycopeptide. Consult Pharm. 2016 Feb;31(2):86-95. doi: 10.4140/TCP.n.2016.86. PMID: 26842686. 5: Thomas G, Henao-Martínez AF, Franco-Paredes C, Chastain DB. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review. Int J Antimicrob Agents. 2020 Sep;56(3):106069. doi: 10.1016/j.ijantimicag.2020.106069. Epub 2020 Jun 27. PMID: 32603683. 6: Schmidt-Malan SM, Greenwood-Quaintance KE, Berglund LJ, Mandrekar J, Patel R. Oritavancin polymethylmethacrylate (PMMA)-compressive strength testing and in vitro elution. J Orthop Surg Res. 2019 Feb 12;14(1):43. doi: 10.1186/s13018-019-1080-6. PMID: 30755223; PMCID: PMC6373086. 7: Saravolatz LD, Stein GE. Oritavancin: A Long-Half-Life Lipoglycopeptide. Clin Infect Dis. 2015 Aug 15;61(4):627-32. doi: 10.1093/cid/civ311. Epub 2015 Apr 21. PMID: 25900171. 8: Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF. Antibiotic penetration into bone and joints: An updated review. Int J Infect Dis. 2019 Apr;81:128-136. doi: 10.1016/j.ijid.2019.02.005. Epub 2019 Feb 14. PMID: 30772469. 9: García Robles AA, López Briz E, Fraga Fuentes MD, Asensi Diez R, Sierra Sánchez JF. Review of oritavancin for the treatment of acute bacterial skin and skin structure infections. Farm Hosp. 2018 Mar 1;42(2):73-81. English. doi: 10.7399/fh.10807. PMID: 29501059. 10: Messina JA, Fowler VG Jr, Corey GR. Oritavancin for acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2015 May;16(7):1091-8. doi: 10.1517/14656566.2015.1026256. Epub 2015 Mar 24. PMID: 25803197; PMCID: PMC4580226.